The FDA has granted priority review to an NDA for taletrectinib in the treatment of advanced ROS1-positive non–small cell ...

IND submission for intranasal SPC-15 treatment expected in 2025; Phase 1 clinical trial to follow upon approvalSP-26 ketamine implants nearing ...

Silo Pharma (SILO) issued a letter to shareholders highlighting the Company’s progress and potential for its lead assets SPC-15 and SP-26 as ...

Subsequent New Drugs, Investigational New Drugs, Fixed Dose Combinations and Bioavailability & Bioequivalence studies," said Dr Rajeev Singh Raghuvanshi, Drugs Controller General (India), in a notice ...

Shares of Viking Therapeutics VKTX have lost nearly 22% in the past six months, significantly underperforming the industry’s ...

At the end of the screening period, Gubra and Amylyx anticipate identifying a lead development candidate to enter Investigational New Drug (IND)-enabling studies. Amylyx then has the option to lead ...

Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement.

The pharma giant pulled out of its partnership with Sangamo, signalling unsteady waters for the latter company and the future ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec ...

Innovent will receive an $80m upfront payment and could earn up to $1bn in development and commercial milestones.

"We are excited to enter this partnership with the Innovent team to further develop this promising investigational treatment for patients ... Innovent has launched 13 products in the market. It has 4 ...

"Imugene doses first Australian subject in trial of B-cell lymphoma drug candidate" was originally created and published by ...